We are studying whether adding Adagrasib to standard chemotherapy and Pembrolizumab helps patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The trial will also evaluate safety and quality of life.
We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.
We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.
We are studying whether combining Niraparib with Bevacizumab improves outcomes for patients receiving chemotherapy for advanced ovarian cancer. This trial aims to see if the combination treatment helps patients live longer without their cancer progressing.
We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.
We are investigating whether sonelokimab can effectively reduce symptoms in adults with active psoriatic arthritis who have not yet tried biologic treatments. The study will also assess the safety of this new medication compared to a placebo.
We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.
We are studying whether adding masitinib to Riluzole helps improve outcomes for people with Amyotrophic Lateral Sclerosis. This trial will assess its safety and effectiveness compared to a placebo.
We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.
We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.
We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.
We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.
We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.
We are studying whether Metformin can effectively slow kidney function decline in adults with Autosomal Dominant Polycystic Kidney Disease compared to Tolvaptan. The trial also examines the safety and impact on kidney size and symptoms.
We are studying MK-7240 to see if it helps people with moderately to severely active ulcerative colitis achieve remission. The trial will also evaluate the safety and effectiveness of this new treatment compared to a placebo.
We are testing a weekly dose of atovaquone-proguanil to see if it can prevent malaria in healthy volunteers. The study also looks at the safety of the medication and how it behaves in the body.
We are investigating a new treatment combining chemotherapy and immunotherapy with radiotherapy for patients with non-metastatic muscle invasive bladder cancer. The goal is to see if this approach improves survival and quality of life after surgery.
We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.
We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.
We are studying the safety and effectiveness of Choline Chloride for Injection in adolescents and adults with intestinal failure. This trial compares the treatment to a placebo to see how well it supports patients receiving long-term parenteral nutrition.